Paricalcitol-d₆ is the deuterium labeled Paricalcitol. Paricalcitol is a agent used for the prevention and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic renal failure.

• . Martinez-Moreno JM, et al. In vascular smooth muscle cells paricalcitol prevents phosphate-induced Wnt/beta-catenin activation. Am J Physiol Renal Physiol. 2012 Aug 8.  [Content Brief]

  . Ari E, Kedrah AE, Alahdab Y, Bulut G, Eren Z, Baytekin O, Odabasi D. Antioxidant and renoprotective effects of paricalcitol on experimental contrast-induced nephropathy model. Br J Radiol. 2012 Aug;85(1016):1038-43.  [Content Brief]

  . Meems LM, Cannon MV, Mahmud H, Voors AA, van Gilst WH, Silljé HH, Ruifrok WP, de Boer RA. The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. J Steroid Biochem Mol Biol. 2012 Jul 16;132(3-5):282-289.  [Content Brief]

  [4]. Blanco-García R, et al. Microalbuminuria, another use for paricalcitol? Our experience in advanced chronic kidney disease. Nefrologia. 2012 May 14;32(3):401-2. doi: 10.3265/Nefrologia.pre2012.Feb.11378.  [Content Brief]

  [5]. Piao SG, Song JC, Lim SW, Chung BH, Choi BS, Yang CW. Protective effect of paricalcitol on cyclosporine-induced renal injury in rats. Transplant Proc. 2012 Apr;44(3):642-5.  [Content Brief]